Biotech Values

[swampboots]

GERN Study PR extraction.: love the swordsmanship which is so inconclusive:

"In these heavily pre-treated patients with high disease burden whose outcome is dismal, imetelstat treatment resulted in multiple clinical meaningful benefits, including symptom response and potential improvement in overall survival. In addition, the reductions in key driver mutations of the disease that were also correlated to clinical benefits suggest disease-modifying activity of imetelstat by targeting the underlying MF malignant clones, which differentiates imetelstat from other therapeutic agents currently in development for MF"

https://cnafinance.com/geron-gern-stock-climbs-on-data-publication/